Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.
Status:
Completed
Trial end date:
2019-01-14
Target enrollment:
Participant gender:
Summary
Pancreatic cancer is the fourth cause of cancer mortality: there are different treatment
approaches to locally advanced pancreatic cancer management.
Generally, gemcitabine alone is considered a reasonable approach for advanced pancreatic
cancer patients but we need a chemotherapeutic regimen able to prevent as much as possible a
progression of the disease. Nab-paclitaxel (Abraxane) recently demonstrated an interesting
activity profile in advanced pancreatic cancer. A combination of Nab-paclitaxel and
gemcitabine has been demonstrated superior to gemcitabine alone in metastatic patients.
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Collaborators:
Istituto Nazionale Tumori di Napoli Unità Sperimentazioni cliniche